A2A Pharmaceuticals, Inc.'s Form 4 filing
Biomea Fusion, Inc. (BMEA) · filed Apr 26, 2023
- Accession no.
- 0001859061-23-000004
- Filed
- Apr 26, 2023
- Trade date
- Apr 20, 2023
- Filing delay
- 6 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $5.82M. It was filed 6 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| A2A Pharmaceuticals, Inc.CIK 0001859061 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 20, 2023 | Common Stock | SSaleDisposed | −200,000 | $29.12F1 | −$5,824,000 | 3,900,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
A total of 200,000 shares were sold at an average price of 29.1188 in multiple transactions in a range of 28.85 to 29.495. Details of the specific transactions are available upon request
Referenced by the price of 1 transaction in Table I.